Corona Virus InfectionNCT04388644
Survey of Satisfaction on Traditional Chinese Medicine Jing-Guan-Fang (JGF) for COVID-19 Prevention
An observational study of Corona Virus Infection, run by Taipei City Hospital at 3 sites in Taiwan.
Trial summary
the retrospective observation study, the first line to care CAVID-19 Read more about this study
- Who is it for?
- Ages 20 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Corona Virus Infection
- How many people
- 300 participants
- Where
- 3 sitesTaiwan
- Study dates
- 20 Feb 2020to 30 May 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The first-line medical staff who take care of COVID-19 patients in public hospital northern Taiwan., and the self-quarantine who have contacted with history. Some of the population will take natural herbal medicine to prevent COVID-19 infection.
Who may be able to join
- The person first-line medical staff in hospital
- the inspection personnel in airport
- self-quarantine at home.
- self-quarantine at office.
Who cannot join
- no willing to participate
- allergy to herbal medicine
- severe illness evaluated by physician
Trial locations and contacts
3 sites in 1 country.
Taiwan3 sites, 3 recruiting
- Recruiting
Branch of Chinese Medicine, Taipei City Hospital
Taipei, 886
Chung-Hua Hsu, MD, PhD, 886-2-23887088 ext. 3828, owlherbs@yahoo.com.tw
WEN-YING SUNG, MD, Master, 886-939309393, tutu9396@gmail.com
- Recruiting
Branch of Linsen Chinese Medicine and Kunming, Taipei City Hospital
Taipei, 886
Chung-Hua Hsu, MD, PhD, 886-2-23887088 ext. 3828, owlherbs@yahoo.com.tw
WEN-YING SUNG, MD, Master, 886-939309393, tutu9396@gmail.com
- Recruiting
Taipei City Hospital
Taipei, 886
Chung Hua Hsu, PhD, 886979306857, dap63@tpech.gov.tw
About this study
Official title: Department of Chinese Medicine, Branch of Linsen, Chinese Medicine, and Kunming, Taipei City Hospital, Taipei, Taiwan Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan.
the retrospective observation study, the first line to care CAVID-19
Read the detailed description
The satisfaction of using nature herbal medicine for frontline medical staffs to prevent COVID-19: a retrospective clinical study.
The medical frontline staffs have the high risk to be infected during working. The stress and load were acuminated, especially when they got the similar symptoms as COVID-19. NHM has been used to early prevention for thousands of years9-12. It was well accept to take NHM for early prevention in many Asia-Pacific countries. Although many NHM remedies of COVID-19 treatment or prevention were reported, but the related study were lacking. To understand the pressure and the satisfaction of frontline medical staffs after taking JGF for early prevention we conducted this retrospective clinical study to explore the relationship in different groups.
- Conditions
- Corona Virus Infection
- Keywords
- natural herbal medicine, Chinese medicine
- Medical subject headings
- Coronavirus Infections
What is being measured
The primary outcome is the main question the study is designed to answer.
the number confirmed COVID-19 cases
The isolated person and first-line care person who taking JGF
Measured: 8 weeks
The person with COVID-19 like symptoms
The isolated person and first-line care person who taking JGF
Measured: 8 weeks
Secondary outcomes (2)
The improving rate of COVID-19 like symptoms
The isolated person and first-line care person who taking JGF
Measured: 8 weeks
The satisfaction% to taking JGF
The isolated person and first-line care person who taking JGF
Measured: 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2020
- Study start20 Feb 2020
- Primary completion20 May 2020 (estimated)
- Study completion30 May 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Corona Virus InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Taipei City Hospital
- Sponsor type
- Other government
- Collaborators
- National Yang Ming Chiao Tung University
- Responsible party
- Sponsor
- Investigators
- Chung-HUa Hsu, PhD, Study director, Taipei City Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04388644
- Sponsor's protocol ID
- TCHIRB-10904015-E
- Status last verified
- Feb 2020
- First submitted
- 12 May 2020
- Last updated
- 14 May 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Department of Chinese Medicine, Branch of Linsen, Chinese Medicine, and Kunming, Taipei City Hospital, Taipei, Taiwan Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan.
- ClinicalTrials.gov ID
- NCT04388644
- Acronym / sponsor ID
- TCHIRB-10904015-E
- Conditions
- Corona Virus Infection
- Keywords
- natural herbal medicine, Chinese medicine
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Taipei City HospitalOther government
- Collaborators
- National Yang Ming Chiao Tung University
- Study start
- 20 Feb 2020 (actual)
- Primary completion
- 20 May 2020 (estimated)
- Study completion
- 30 May 2020 (estimated)
- First posted
- 14 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
the retrospective observation study, the first line to care CAVID-19
Detailed description
The satisfaction of using nature herbal medicine for frontline medical staffs to prevent COVID-19: a retrospective clinical study.
The medical frontline staffs have the high risk to be infected during working. The stress and load were acuminated, especially when they got the similar symptoms as COVID-19. NHM has been used to early prevention for thousands of years9-12. It was well accept to take NHM for early prevention in many Asia-Pacific countries. Although many NHM remedies of COVID-19 treatment or prevention were reported, but the related study were lacking. To understand the pressure and the satisfaction of frontline medical staffs after taking JGF for early prevention we conducted this retrospective clinical study to explore the relationship in different groups.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 20 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The first-line medical staff who take care of COVID-19 patients in public hospital northern Taiwan., and the self-quarantine who have contacted with history. Some of the population will take natural herbal medicine to prevent COVID-19 infection.
Key inclusion criteria (4 listed)
- The person first-line medical staff in hospital
- the inspection personnel in airport
- self-quarantine at home.
- self-quarantine at office.
Key exclusion criteria (3 listed)
- no willing to participate
- allergy to herbal medicine
- severe illness evaluated by physician
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
the number confirmed COVID-19 cases
Time frame: 8 weeks
The isolated person and first-line care person who taking JGF
The person with COVID-19 like symptoms
Time frame: 8 weeks
The isolated person and first-line care person who taking JGF
2 secondary outcomes
The improving rate of COVID-19 like symptoms
Time frame: 8 weeks
The satisfaction% to taking JGF
Time frame: 8 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2020.
- Individual participant dataSharing planned: No
Related trials for Corona Virus Infection
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
RecruitingObservational study
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Pneumonia, Community-Acquired, COVID-19 Pneumonia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chung-HUa Hsu, PhD study director
Taipei City Hospital
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Corona Virus Infection, run by Taipei City Hospital at 3 sites in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 May 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Chung Hua Hsu, PhD (886-2-23887088 ext. 3100, dap63@tpech.gov.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the number confirmed COVID-19 cases (time frame: 8 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2020.